

10TH ANNUAL(VIRTUAL) MEETING OF THE LUPUS ACADEMY

EARLY SESSIONS: 6TH, 9TH AND 12TH APRIL 2021

VIRTUAL MEETING: 16–18TH APRIL 2021

www.lupusacademy.org

LUPUS ACADEMY 10TH ANNUAL MEETING: EARLY SESSIONS (ONLINE)

SESSION 1: SLE TREATMENT DILEMMAS

Tuesday 6th April 2021: 14:00–15:30 hours CET (UTC+2 Paris, Amsterdam, Berlin)

<i>Moderators: Andrea Doria (Italy), Ronald van Vollenhoven (Netherlands)</i>	
Should we vaccinate all SLE patients against papillomavirus and herpes zoster? <i>Q&A and Discussion (15 Mins)</i>	<i>Sarfaraz Hasni (USA)</i>
Hydroxychloroquine myopathy: cardiac and skeletal muscle toxicity <i>Q&A and Discussion (15 Mins)</i>	<i>Murray Urowitz (Canada)</i>
Low dose aspirin in aPL-positive patients: Are we treating the patient or the doctor? <i>Q&A and Discussion (15 Mins)</i>	<i>Denis Wahl (France)</i>

SESSION 2: THE ROLE OF INTERFERONS IN SLE

Friday 9th April 2021: 14:00–15:30 hours CET (UTC+2 Paris, Amsterdam, Berlin)

<i>Moderators: Richard Furie (USA), Zahir Amoura (France)</i>	
Biology of interferons <i>Q&A and Discussion (15 Mins)</i>	<i>Mary Crow (USA)</i>
How interferonopathies inform SLE pathogenesis <i>Q&A and Discussion (15 Mins)</i>	<i>Yanick Crow (UK)</i>
Interferon inhibition and the future management of SLE <i>Q&A and Discussion (15 Mins)</i>	<i>Eric Morand (Australia)</i>

SESSION 3: LESSONS LEARNED FROM OTHER DISEASES

Monday 12th April 2021: 14:00–16:00 hours CET (UTC+2 Paris, Amsterdam, Berlin)

<i>Moderators: Eloisa Bonfa (Brazil), Ronald van Vollenhoven (Netherlands)</i>	
Lessons from transplantation: Multitargeted therapy for proliferative lupus nephritis <i>Q&A and Discussion (15 Mins)</i>	<i>Daniel Tak Mao Chan (Hong Kong)</i>
Lessons from ITP: Treatment of refractory thrombocytopenia <i>Q&A and Discussion (15 Mins)</i>	<i>Sacha Zeerleder (Netherlands)</i>
Lessons from scleroderma: Treatment of interstitial lung disease in SLE <i>Q&A and Discussion (15 Mins)</i>	<i>Oliver Distler (Switzerland)</i>
Lessons from RA: RA drug development has advanced at a more rapid pace than SLE: What can we learn from our colleagues? <i>Q&A and Discussion (15 Mins)</i>	<i>Ronald van Vollenhoven (Netherlands)</i>

OPENING SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 13:00–15:15 hours

Opening	Zahir Amoura (France), Richard Furie (USA)
Keynote	
<i>Moderator: Richard Furie (USA)</i>	
Kidney biopsies in SLE: Too few or too many? <i>Q&A and Discussion (15 Mins)</i>	Hans-Joachim Anders (Germany)
Debate: In With the New, Out With Old? Should All Patients with Lupus Nephritis Receive New Generation Therapies in Addition to Established Standard of Care?	
<i>Moderator: Ronald van Vollenhoven (Netherlands)</i>	
The matter of the debate (10 mins)	Ronald van Vollenhoven (Netherlands)
All lupus nephritis patients should be initially managed with both established standard therapies and the new generation drugs (20 mins + 10 mins rebuttal)	Onno Teng (Netherlands)
All lupus nephritis patients should be initially managed with established standard therapies alone (20 mins + 10 mins rebuttal)	Dimitrios Boumpas (Greece)
<i>Voting, Q&A and Discussion (20 Mins)</i>	All

PLENARY I: NOVEL STRATEGIES FOR OPTIMIZING OUTCOMES IN SLE

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30–17:30 hours

<i>Moderators: Sandra Navarra (Philippines)</i>	
Preventing damage and reducing mortality in lupus. How are we doing? <i>Q&A and Discussion (15 Mins)</i>	Murray Urowitz (Canada)
Strategies for minimizing corticosteroid exposure in SLE <i>Q&A and Discussion (15 Mins)</i>	Zahir Amoura (France)
Targeting remission and low disease activity in SLE <i>Q&A and Discussion (15 Mins)</i>	Andrea Doria (Italy)
Lupus treatment in the next decade: The next decade is upon us <i>Q&A and Discussion (15 Mins)</i>	Richard Furie (USA)

OPENING SESSION (PRE-RECORDED)*

CET (UTC+2 Paris, Amsterdam, Berlin) 18:00–20:15 hours

Opening	Zahir Amoura (France), Richard Furie (USA)
Keynote	
<i>Moderator: Richard Furie (USA)</i>	
Kidney biopsies in SLE: Too few or too many? <i>Recorded Q&A and Discussion (15 Mins)</i>	Hans-Joachim Anders (Germany)
Debate: In With the New, Out With Old? Should All Patients with Lupus Nephritis Receive New Generation Therapies in Addition to Established Standard of Care?	
<i>Moderator: Ronald van Vollenhoven Netherlands</i>	
The matter of the debate (10 mins)	Ronald van Vollenhoven (Netherlands)
All lupus nephritis patients should be initially managed with both established standard therapies and the new generation drugs (20 mins + 10 mins rebuttal)	Onno Teng (Netherlands)
All lupus nephritis patients should be initially managed with established standard therapies alone (20 mins + 10 mins rebuttal)	Dimitrios Boumpas (Greece)
<i>Recorded Voting, Q&A and Discussion (20 Mins)</i>	All

*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

PLENARY I: NOVEL STRATEGIES FOR OPTIMIZING OUTCOMES IN SLE (PRE-RECORDED)***CET (UTC+2 Paris, Amsterdam, Berlin) 07:00–09:00 hours**

<i>Moderators: Sandra Navarra (Philippines)</i>	
Preventing damage and reducing mortality in lupus. How are we doing? <i>Recorded Q&A and Discussion (15 Mins)</i>	<i>Murray Urowitz (Canada)</i>
Strategies for minimizing corticosteroid exposure in SLE <i>Recorded Q&A and Discussion (15 Mins)</i>	<i>Zahir Amoura (France)</i>
Targeting remission and low disease activity in SLE <i>Recorded Q&A and Discussion (15 Mins)</i>	<i>Andrea Doria (Italy)</i>
Lupus treatment in the next decade: The next decade is upon us <i>Recorded Q&A and Discussion (15 Mins)</i>	<i>Richard Furie (USA)</i>

*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

CASE STUDY INTERACTIVE WORKSHOPS**CET (UTC+2 Paris, Amsterdam, Berlin) 09:00–10:30 hours**

<i>Moderator/Facilitator: Andrea Doria (Italy)</i>	
Cutaneous lupus	<i>Bernardo Pons-Estel (Argentina), Annegret Kuhn (Germany)</i>
<i>Moderator/Facilitator: Sandra Navarra (Philippines)</i>	
Lupus nephritis	<i>Liz Lightstone (UK), Sandra Navarra (Philippines)</i>
<i>Moderator/Facilitator: David Isenberg (UK)</i>	
Paediatric SLE	<i>Alexandre Belot (France), Rolando Cimaz (Italy)</i>
<i>Moderator/Facilitator: Murray Urowitz (Canada)</i>	
Neuropsychiatric SLE	<i>Ricard Cervera (Spain)/ Thomas Huizinga (NL)</i>
<i>Moderator/Facilitator: Eloisa Bonfa (Brazil)</i>	
Reproductive health in SLE	<i>Lisa Sammaritano (USA), Rebecca Fischer-Betz (Germany)</i>

HOT TOPICS: THE ROLE OF COMPLEMENT IN SLE**CET (UTC+2 Paris, Amsterdam, Berlin) 11:00–13:00**

<i>Moderators: Thomas Dörner (Germany), David Isenberg (UK)</i>	
Complement in SLE <i>Q&A and Discussion (15 Mins)</i>	<i>John Atkinson (USA)</i>
The role of complement and complement inhibition in APS pregnancy <i>Q&A and Discussion (15 Mins)</i>	<i>Jane Salmon (USA)</i>
The interface of the complement and coagulation pathways <i>Q&A and Discussion (15 Mins)</i>	<i>Edward Conway (Canada)</i>
Lessons learned from complement inhibition in ANCA vasculitis <i>Q&A and Discussion (15 Mins)</i>	<i>David Jayne (UK)</i>

PRIME TIME SESSION**CET (UTC+2 Paris, Amsterdam, Berlin) 13:30–15:30 hours**

Hot Topics: Highlighting Accomplishments in Lupus Research	
<i>Moderators: Murray Urowitz (Canada), David Isenberg (UK)</i>	
Translational insights into the pathogenesis transforming SLE treatment <i>Q&A and Discussion (15 Mins)</i>	<i>Thomas Dörner (Germany)</i>
Clinical science highlights that are transforming treatment <i>Q&A and Discussion (15 Mins)</i>	<i>Bevra Hahn (USA)</i>
Thieves' Market	
<i>Moderators: Richard Furie (USA), Eloisa Bonfa (Brazil)</i>	

Case in practice: Neither arms NOR legs were feeling well <i>Q&A (10 Mins)</i>	<i>Eduardo Dourado (Portugal)</i>
Case in practice: Born together, best friends together <i>Q&A (10 Mins)</i>	<i>Rinat Raupov (Russia)</i>
Case in practice: A short hi-storiform of time in clinic <i>Q&A (10 Mins)</i>	<i>Saskia Rowson (Australia)</i>
<i>Voting and Panel Discussion</i>	

CASE STUDY INTERACTIVE WORKSHOPS

CET (UTC+2 Paris, Amsterdam, Berlin) 16:30–18:00 hours

<i>Moderator/Facilitator: Andrea Doria (Italy)</i>	
Cutaneous lupus	<i>Bernardo Pons-Estel (Argentina)</i> <i>Annegret Kuhn (Germany),</i>
<i>Moderator/Facilitator: Sandra Navarra (Philippines)</i>	
Lupus nephritis	<i>Liz Lightstone (UK),</i> <i>Sandra Navarra (Philippines)</i>
<i>Moderator/Facilitator: David Isenberg (UK)</i>	
Paediatric SLE	<i>Alexandre Belot (France),</i> <i>Rolando Cimaz (Italy)</i>
<i>Moderator/Facilitator: Murray Urowitz (Canada)</i>	
NPSLE	<i>Ricard Cervera (Spain)/</i> <i>Thomas Huizinga (NL)</i>
<i>Moderator/Facilitator: Eloisa Bonfa (Brazil)</i>	
Reproductive health in SLE	<i>Lisa Sammaritano (USA),</i> <i>Rebecca Fischer-Betz (Germany)</i>
Close	

HOT TOPICS: THE ROLE OF COMPLEMENT IN SLE (PRE-RECORDED)*

CET (UTC+2 Paris, Amsterdam, Berlin) 18:30–20:30

<i>Moderators: Thomas Dörner (Germany) , David Isenberg (UK)</i>	
Complement in SLE <i>Q&A and Discussion (15 Mins)</i>	<i>John Atkinson (USA)</i>
The role of complement and complement inhibition in APS pregnancy <i>Q&A and Discussion (15 Mins)</i>	<i>Jane Salmon (USA)</i>
The interface of the complement and coagulation pathways <i>Q&A and Discussion (15 Mins)</i>	<i>Edward Conway (Canada)</i>
Lessons learned from complement inhibition in ANCA vasculitis <i>Q&A and Discussion (15 Mins)</i>	<i>David Jayne (UK)</i>

*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

PLENARY II: TREATMENT CHALLENGES**CET (UTC+2 Paris, Amsterdam, Berlin) 09:00–11:00 hours**

<i>Moderators: Zahir Amoura (France)</i>	
Treatment of CAPS: Which drugs and in which order? <i>Q&A and Discussion (15 Mins)</i>	<i>Marc Pineton de Chambrun (France)</i>
Refractory cutaneous lupus: Use of thalidomide or lenalidomide for refractory lupus skin disease <i>Q&A and Discussion (15 Mins)</i>	<i>François Chasset (France)</i>
Osteonecrosis: Prevention and treatment <i>Q&A and Discussion (15 Mins)</i>	<i>Bernardo Pons Estel (Argentina)</i>
Alveolar hemorrhage <i>Q&A and Discussion (15 Mins)</i>	<i>Ricard Cervera (Spain)</i>

POSTER SESSION*: PRESENTATIONS**CET (UTC+2) Paris, Amsterdam, Berlin) 11:30–12:30 hours**

<i>Moderators: Andrea Doria (Italy), Ronald van Vollenhoven (Netherlands)</i>	
Incorporation of Banff classification in Lupus histopathology assessment emphasizes the importance of tubulointerstitial changes <i>Q&A (5 Mins)</i>	<i>Peter Korsten (Germany)</i>
ISG15 deficiency underlie monogenic lupus with inflammatory myositis <i>Q&A (5 Mins)</i>	<i>Lujayn Akbar (Saudi Arabia)</i>
Immunophenotype of systemic lupus erythematosus and Sjögren's syndrome patients identified two endotypes with potential therapeutic implications <i>Q&A (5 Mins)</i>	<i>Lucia Martin-Gutierrez (UK)</i>
Comparison of different definitions of remission in children with lupus nephritis <i>Q&A (5 Mins)</i>	<i>Chiara De Mutiis (Italy)</i>
Multi-omic analysis identifies dyslipidaemia in juvenile-SLE patients associated with disease activity, inflammation and atherosclerosis <i>Q&A (5 Mins)</i>	<i>George Robinson (UK)</i>

*More Posters Available Online

MEETING HIGHLIGHTS**CET (UTC+2) Paris, Amsterdam, Berlin) 13:00–14:00 hours**

<i>Moderators: Zahir Amoura (France), Richard Furie (USA)</i>	
Meeting Highlights	<i>Eloisa Bonfa (Brazil); David Isenberg (UK); Richard Furie (USA); Zahir Amoura (France)</i>
Questions and Answers (Live)	<i>Steering Committee</i>
Close	<i>Zahir Amoura (France), Richard Furie (USA)</i>

MEET THE EDITOR**CET (UTC+2) Paris, Amsterdam, Berlin) 14:15 – 15:00 hours**

<i>Moderator: Ronald van Vollenhoven (Netherlands)</i>	
Introduction: What is happening in the world of publishing?	<i>Ronald van Vollenhoven (Netherlands)</i>
Workshop: How do I get my manuscript published—in the best possible journal?	
Tips for reviewers: make it work for the authors and yourself	

PLENARY II: TREATMENT CHALLENGES (PRE-RECORDED)***CET (UTC+2 Paris, Amsterdam, Berlin) 15:30–17:30 hours**

<i>Moderators: Zahir Amoura (France)</i>
--

Treatment of CAPS: Which drugs and in which order? <i>Q&A and Discussion (15 Mins)</i>	<i>Marc Pineton (France)</i>
Refractory cutaneous lupus: Use of thalidomide or lenalidomide for refractory lupus skin disease <i>Q&A and Discussion (15 Mins)</i>	<i>François Chasset (France)</i>
Osteonecrosis: Prevention and treatment <i>Q&A and Discussion (15 Mins)</i>	<i>Bernardo Pons Estel (Argentina)</i>
Alveolar hemorrhage <i>Q&A and Discussion (15 Mins)</i>	<i>Ricard Cervera (Spain)</i>

*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.